The Promise and Challenge of Type 1 Diabetes Care: Why Access Still Matters

The discovery of insulin a century ago fundamentally changed type 1 diabetes from a fatal disease to one people could live with. That breakthrough set the stage for the next major shift: understanding that type 1 diabetes is an autoimmune condition. This insight changed everything. It meant scientists could look for the disease before symptoms ever appeared and potentially intervene early.

Today, screening programs in research settings are identifying people with presymptomatic type 1 diabetes—people who don't yet feel sick but whose immune systems are already attacking insulin-producing cells. This early detection matters because it opens a window for disease-modifying therapy before clinical onset.

For people already living with type 1 diabetes, two technologies have made a real difference: continuous glucose monitors (CGMs) and automated insulin delivery (AID) systems. These tools work together to give people better control, fewer dangerous blood sugar swings, and—importantly—more freedom in their daily lives.

CGMs track blood sugar continuously, while AID systems automatically adjust insulin delivery. The result is safer insulin therapy, better overall blood sugar control, and a measurable improvement in quality of life for users.

The gap between what's possible and what's available is stark. Screening programs remain geographically limited, meaning people in some areas have no way to participate. The same is true for CGMs and AID systems—access varies dramatically between countries and even within them.

These disparities follow familiar fault lines: socioeconomic circumstances, geographic location, racial and ethnic background, and access to specialist care all shape who gets to benefit from these advances and who doesn't.

Research shows that type 1 diabetes screening and these newer technologies are cost-effective—meaning the health benefits justify the investment. That evidence should matter for policy makers deciding how to spend healthcare dollars and which treatments to cover.

But evidence of cost-effectiveness alone isn't enough to close the gap. Truly equitable access requires addressing the deeper structural differences in healthcare access, specialist care, and resources across different communities and countries. The science and technology are here. The challenge now is making sure they reach everyone who needs them.

Source: Journal of diabetes investigation. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.